Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor in combination with standard therapy for newly diagnosed or recurrent glioblastoma
MOH_2021-09-12_010232Phase 2Recruiting
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of selinexor in glioblastoma (GBM) (5 arms), sponsored by Karyopharm Therapeutics Inc. Started Aug 2021; status: recruiting.
02
Drugs
selinexor
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on MOH_2021-09-12_010232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-09-12_010232.